Elicio Therapeutics (ELTX) Investor presentation summary

Platform and development strategy

• AMP is designed to bind endogenous albumin after subcutaneous injection, target lymph nodes and deliver antigens to immune cells, supporting T- and B-cell responses, expansion, persistence and effector function.

• Pipeline spans camupepimut in adjuvant, metastatic and neoadjuvant mKRAS-positive PDAC; planned expansion includes mKRAS colorectal cancer and ELI-007/ELI-008 for other solid-tumor targets.

• Planned metastatic PDAC Phase 1 combines camupepimut with Rasonque, with or without nivolumab; initiation was expected in Q4 2026, with readouts anticipated 3–6 months after study start.

• Neoadjuvant Phase 1 is designed to assess camupepimut with mFOLFIRINOX, with or without tislelizumab, in resectable or borderline-resectable mKRAS-positive PDAC; primary endpoint is safety.

AMPLIFY-7P trial and efficacy

• Randomized Phase 2 enrolled 144 resected Stage I–III mKRAS-positive PDAC patients; 96 received camupepimut and 48 observation, with disease-free survival (DFS) as the primary endpoint.

• The primary ITT DFS endpoint was not met: median DFS was 23.8 months with camupepimut vs 21.2 months with observation (HR 0.85; p=0.5329); 6-month DFS was 75.7% vs 61.7%.

• After adjustment for baseline prognostic factors, camupepimut was associated with a 53% lower risk of recurrence or death (HR 0.47; p=0.0086); Stage III, elevated CA19-9 and ctDNA positivity were adverse prognostic factors.

• Baseline ctDNA positivity was associated with higher recurrence or death risk (HR 6.56; median DFS 4.2 vs 24.0 months); prespecified treatment effects favored camupepimut in ctDNA-negative and ctDNA-positive subgroups (HR 0.51 and 0.57).

• Phase 2 findings inform a proposed Phase 3 precision strategy with refined eligibility, extended dosing and potential checkpoint-inhibitor combination evaluation.

Immune response and safety

• Camupepimut induced mKRAS-specific T-cell responses in 99% of evaluable patients (89/90); 82% (74/90) had more than 9.17-fold expansion, with responses across seven KRAS variants.

• In Phase 2, patients with at least 9.17-fold T-cell expansion had improved DFS vs lower responders (HR 0.22; p<0.0001); a similar association was observed in Phase 1 (HR 0.12; p=0.0002).

• Grade ≥3 TEAEs occurred in 10.4% with camupepimut vs 14.6% with observation; serious TEAEs were 6.3% vs 8.3%, and no treatment-related deaths or toxicity-related withdrawals were reported.